Found 721 Enz. Inhib. hit(s) with Target = 'Vascular endothelial growth factor receptor 3' TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 11nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 25nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 64nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 76nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 52nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 23nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 526nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 68nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 394nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 173nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 329nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 315nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 26nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 17nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 75nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 267nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 9nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 30nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 4nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 62nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 5nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 14nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 7nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 9nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 16nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 31nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 32nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 44nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 160nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 45nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 154nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 12nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 9nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 3nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 13nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 5nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 12nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 23nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 46nMpH: 7.4Assay Description:A biotin labelled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)....More data for this Ligand-Target Pair
